HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BNC 105P

prodrug of BNC105

Also Known As:

BNC-105P; BNC105P

Networked: 7 relevant articles (0 outcomes, 5 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzofurans: 26
      - BNC 105P: 7
Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Organophosphates: 1942
    - BNC 105P: 7

Experts

1.	Kremmidiotis, Gabriel: 5 articles (01/2019 - 08/2011)
2.	Bibby, David C: 3 articles (08/2015 - 08/2011)
3.	Leske, Annabell F: 3 articles (09/2013 - 08/2011)
4.	Doolin, Elizabeth: 2 articles (01/2019 - 08/2015)
5.	Lavranos, Tina C: 2 articles (01/2019 - 09/2011)
6.	Leske, Annabell: 2 articles (01/2019 - 08/2015)
7.	Rischin, Danny: 2 articles (01/2019 - 08/2011)
8.	Simpson, Jeremy: 2 articles (01/2019 - 08/2015)
9.	Stockler, Martin R: 2 articles (01/2019 - 09/2013)
10.	Adib, Elio: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2011 - "Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation." 01/01/2021 - "To address this hypothesis, tumors from a phase I/II trial that compared everolimus alone or with BNC105P, a vascular disrupting agent, were profiled using Nanostring as a discovery cohort. " 09/01/2013 - "BNC105P is a tubulin polymerisation inhibitor that selectively disrupts tumour vasculature and suppresses cancer cell proliferation. " 09/08/2011 - "Because of poor solubility, 8 is administered as its disodium phosphate ester prodrug 9 (BNC105P), which is rapidly cleaved in vivo to return the active 8. 9 exhibits both superior vascular disrupting and tumor growth inhibitory properties compared with the benchmark agent combretastatin A-4 disodium phosphate 5 (CA4P)."
2.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/01/2022 - "A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia."
3.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2019 - "Further exploration of BNC105P in the ovarian cancer setting is planned." 01/01/2019 - "The primary objective of this study was to determine the recommended dose of the vascular disrupting agent, BNC105P, in combination with gemcitabine and carboplatin in patients with ovarian cancer in first or second relapse with a minimum 4 month progression-free interval after last platinum. " 01/01/2019 - "Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)."
4.	Renal Cell Carcinoma (Grawitz Tumor) 08/01/2015 - "A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma."
5.	Thrombocytopenia (Thrombopenia) 01/01/2019 - "Dose-limiting toxicities (thrombocytopenia and neutropenia) occurred in two patients at the dose level of 800 mg/m2 gemcitabine, carboplatin AUC4 and 16 mg/m2 BNC105P. "

Related Drugs and Biologics

1.	Everolimus
2.	Carboplatin (JM8)
3.	Platinum
4.	Gemcitabine
5.	ibrutinib
6.	Tubulin
7.	Prodrugs
8.	Phosphates (Orthophosphate)
9.	Esters
10.	fosbretabulin (combretastatin A4)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)